Testing how the tumor environment affects pre-op chemo plus immunotherapy
Part of Cancer, Digestive system clinical trials.
This study looks at people with esophageal squamous cell carcinoma to see how changes in the “tumor neighborhood” may affect how well treatment works before surgery. If you’re eligible, you would receive chemotherapy plus immunotherapy as neoadjuvant (before-surgery) treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have esophageal squamous cell carcinoma confirmed by pathology (a lab diagnosis from tissue).
- Your cancer stage is II to IVA, and you are planning pre-surgery treatment (neoadjuvant).
- You will have chemotherapy plus immunotherapy before surgery.
- Your health status is very good to good (ECOG score 0 to 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether adding immunotherapy to chemotherapy before surgery works better than chemotherapy alone for resectable esophageal cancer. The goal is to improve outcomes after tumor shrinkage before the operation.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This study looks at how the tumor's surroundings change when you receive a combination of chemotherapy and immunotherapy before surgery for esophageal squamous cell carcinoma. The goal is to understand if this treatment approach is effective and how the tumor reacts, which may help guide future care.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.